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Abstract
Background: Systemic inflammation is associated with increased cognitive decline and risk for Alzheimer’s disease.
Microglia (MG) activated during systemic inflammation can cause exaggerated neuroinflammatory responses and
trigger progressive neurodegeneration. Dimethyl fumarate (DMF) is a FDA-approved therapy for multiple sclerosis.
The immunomodulatory and anti-oxidant properties of DMF prompted us to investigate whether DMF has
translational potential for the treatment of cognitive impairment associated with systemic inflammation.
Methods: Primary murine MG cultures were stimulated with lipopolysaccharide (LPS) in the absence or presence
of DMF. MG cultured from nuclear factor (erythroid-derived 2)-like 2-deficient (Nrf2−/−) mice were used to examine
mechanisms of DMF actions. Conditioned media generated from LPS-primed MG were used to treat hippocampal
neuron cultures. Adult C57BL/6 and Nrf2−/− mice were subjected to peripheral LPS challenge. Acute neuroinflammation,
long-term memory function, and reactive astrogliosis were examined to assess therapeutic effects of DMF.
Results: DMF suppressed inflammatory activation of MG induced by LPS. DMF suppressed NF-κB activity through Nrf2-
depedent and Nrf2-independent mechanisms in MG. DMF treatment reduced MG-mediated toxicity towards neurons.
DMF suppressed brain-derived inflammatory cytokines in mice following peripheral LPS challenge. The suppressive effect
of DMF on neuroinflammation was blunted in Nrf2−/− mice. Importantly, DMF treatment alleviated long-term memory
deficits and sustained reactive astrogliosis induced by peripheral LPS challenge. DMF might mitigate neurotoxic astrocytes
associated with neuroinflammation.
Conclusions: DMF treatment might protect neurons against toxic microenvironments produced by reactive MG and
astrocytes associated with systemic inflammation.
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Background
Dementia causes severe memory loss and destroys func-
tional independence in affected individuals. Mounting
evidence indicates that systemic inflammation acts as a
significant driver of neurodegeneration and development
of dementia [1]. Acute systemic inflammatory traumas
not only cause profound cognitive dysfunction, such as
delirium, but also lead to long-term cognitive decline
and increase risk of developing dementia [2–4]. Low-
grade peripheral inflammation chronically affects the
volume of the hippocampus and increases risk of cogni-
tive deficits in late life [5, 6]. During the progression of
aging, the human body accumulates inflammatory
attacks through repeated microbial infections, tissue
injuries, or chronic disorders, such as obesity, diabetes, or
atherosclerosis. Systemic inflammation caused by these in-
flammatory comorbidities can robustly alter brain inflam-
matory status through inducing phenotypic changes of the
brain resident immune cells, microglia (MG).
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MG play critical roles in maintaining tissue homeosta-
sis of the brain. Upon stimulation, MG undergo a dy-
namic spectrum of activation patterns and change their
functional properties [7–9]. Classically activated MG
produce robust pro-inflammatory cytokines, including
tumor necrosis α (TNFα), interleukin-1β (IL-1β), IL-12,
and IL-6. The inflammatory activation of reactive MG
contributes to the pathogenesis of neurodegeneration in
various human neurological disorders [10]. Dysregula-
tion in microglial activation leads to accumulations of
“primed” MG that tend to react strongly to the stimuli
from the periphery and get activated towards inflamma-
tory phenotypes. Activated inflammatory MG trigger
and orchestrate the process leading to chronic neuroin-
flammation and neurodegeneration [10].
Dimethyl fumarate (DMF) is a fumaric acid ester that
is commonly used to treat psoriasis [11, 12]. The
delayed-released DMF is approved as a therapy for the
treatment of multiple sclerosis (MS) after showing its ef-
ficacy on reducing relapse rate and the number of new
lesions in phase III clinical trials [13, 14]. DMF and its
metabolites, monomethyl fumarate (MMF), exhibit im-
munomodulatory and anti-oxidant properties [15]. DMF
stimulates anti-inflammatory responses and reduces
oxidative stress by activating the nuclear factor (eryth-
roid-derived 2)-like 2 (Nrf2), a transcription factor regu-
lating anti-oxidant response pathways [16, 17]. Under
normal conditions, Nrf2 is sequestered in the cytoplasm
by Kelch ECH-associated protein 1 (Keap1) binding and
is degraded through the ubiquitin-proteasome pathway.
Application of DMF stabilizes Nrf2 and promotes its tran-
scriptional activities. Nrf2 binds the antioxidant response
elements (ARE) located within gene promoters and
induces expressions of detoxification and anti-oxidant
enzymes such as hemoxygenase-1 (HO-1), NADPH quin-
one oxidoreductase-1 (NQO1), glutamate-cysteine ligase,
catalytic subunit (Gclc), and glutamate-cysteine ligase
regulatory subunit (Gclm). However, the DMF mechanism
of action is not fully understood. Nrf2-independent mech-
anisms may be involved in the therapeutic effects of DMF
in MS [18, 19].
In chronic autoimmune disorders, such as MS, MG
are thought to sustain the inflammatory responses that
are initially triggered by infiltrating T cells from the per-
iphery. Activated MG propagate neuroinflammation and
drive disease evolution into the progressive phase, lead-
ing to irreversible demyelination and axonal loss [9, 20].
Reactive MG induced by systemic inflammation might
result in progressive inflammation inside the brain,
leading to neurodegeneration and subsequently cognitive
impairment. In this study, we investigated the potential ef-
fects of DMF on modulating reactive MG associated with
systemic inflammation. Our results demonstrate that
DMF significantly suppresses acute neuroinflammation
following peripheral lipopolysaccharide (LPS) challenge in
mice. DMF treatment alleviates long-term memory defi-
cits and mitigates reactive A1-like astrocytes associated
with systemic inflammation.
Methods
Animals
C57BL/6, Cx3cr1gfp/+, and Nrf2−/− mice were purchased
from the Jackson Laboratory and bred at the animal
facility of Indiana University School of Medicine, Fort
Wayne. Mice were housed and maintained at 25 °C
under a 12-h light/12-h dark cycle with ad libitum access
to food and water. Adult female mice aged at 12–
16 weeks were used for studies. All animal procedures in
this study were conducted in accordance with the
National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals and approved by Purdue
Animal Care and Use Committee.
Reagents
Dimethyl fumarate (DMF) was purchased from Tocris
Bioscience (Minneapolis, MN). Lipopolysaccharide (LPS;
Escherichia coli O55:B5) and dimethyl sulfoxide (DMSO)
were purchased from Sigma-Aldrich (St. Louis, MO). JC-1
dye (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazo-
lylcarbocyanine iodide) was purchased from Thermo
Fisher Scientific. Antibodies used for fluorescence-
activated cell sorting (FACS) analysis were purchased from
BioLegend (San Diego, CA): PE-conjugated anti-mouse
CD11b (clone: M1/70) and CD86 (clone: PO3), PE/Cy7-
conjugated anti-mouse CD80 (clone: 16-10A1), and
APC-conjugated anti-mouse CD40 (clone: 3/23). For the
western blot analysis, rabbit anti-Nrf2 and anti-HO-1 anti-
bodies were purchased from Proteintech (Chicago, IL).
Rabbit anti-phospho-IKK-α/β and rabbit anti-inducible
nitric oxide synthase (iNOS) antibodies were purchased
from Cell Signaling (Danvers, MA). For immunostaining
of astrocytes, mouse anti-glial fibrillary acidic protein
(GFAP) antibody was purchased from Cell Signaling
(Danvers, MA); rabbit anti-aquaporin-4 (Aqp4) antibody
was purchased from Sigma-Aldrich. Recombinant mouse
TNFα and IL-1α were purchased from BioLegend (San
Diego, CA).
Cell culture and drug treatment
Primary MG cells were obtained as previously described
with some modifications [21]. Briefly, cells were cultured
in medium DMEM/F12 containing 10% heated-
inactivated fetal bovine serum, 2 mM L-glutamine, and
1X antibiotic/antimycotic. The medium was supple-
mented with 5 ng/ml granulocyte macrophage-colony
stimulating factor (GM-CSF) on days in vitro (DIV) 5
and 10 after plating. On DIV 15, MG were harvested by
shaking the flasks. The purity of MG cells was examined
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using FACS analysis. More than 95% of harvested cells
were positive for CD11b expression (Additional file 1:
Figure S1A). MG cells were seeded at desired densities
and pre-treated with DMF (0, 10, and 100 μM in culture
medium containing 0.001% DMSO final concentration)
for 1 h and then stimulated with 100 ng/ml LPS for vari-
ous times as indicated in the text and/or figure legends.
The working concentration of LPS was prepared from
the stock using culture medium as the diluent. Enriched
astrocyte cultures were prepared as previously described
[22]. Briefly, cells were harvested and maintained in the
same medium for primary MG in the absence of GM-
CSF. On DIV 8, MG and oligodendrocyte precursor cells
growing on the top of confluent astrocyte monolayer
were detached by shaking at 250 rpm for 6 h. The
astrocyte layer was detached using trypsin EDTA and
re-plated to cell culture flasks. On DIV 20, enriched as-
trocytes were prepared and seeded at desire density for
experiments. The purity of enriched astrocyte cultures
was examined using the GFAP and Aqp4 immunostain-
ing analysis, showing 70–75% of cells are GFAP+ and
Aqp4+ astrocytes (Additional file 1: Figure S1C). The
astrocyte cultures were pre-treated with DMF (0 and
100 μM) for 1 h followed by TNFα (30 ng/ml) and IL-1α
(3 ng/ml) stimulation for 24 h as indicated.
RNA isolation and real-time PCR
Total RNAs were isolated from cells or tissues using
RNeasy RNA isolation kit (Qiagen). cDNAs were pre-
pared by reverse transcription using High-Capacity
cDNA Reverse Transcription Kit with random primers
(Life Technologies, CA). Quantitative real-time PCR
(qPCR) was performed using TaqMan gene expression
probes and PCR Master Mix (Applied Biosystems, Life
Technologies, CA).
Immunocytochemistry and confocal microscopy
Primary MG were treated as described. After treat-
ment, cells were fixed in 2% paraformaldehyde follow-
ing with phosphate-buffered saline (PBS) wash. Cells
were permeabilized and blocked with 3% normal goat
serum for 30 min at room temperature (RT). Cells
were incubated with primary antibodies, rabbit anti-
Iba1 (WAKO, Richmond, VA), rabbit anti-NF-κB p65
or anti-cleaved Caspase-3 (Cell Signaling, Danvers,
MA) for 1 h at RT. After washing, cells were incu-
bated with Alexa Fluor 594-conjugated goat anti-
rabbit (Life Technologies, CA) for 1 h at RT. After
washing, cell nuclei were counterstained with Hoechst
33342 (Life Technologies, CA). Images were acquired
on Fluoview FV10i confocal microscope with an × 60
objective using the FV10iO software (Olympus) and
analyzed using ImageJ, NIH.
Western blotting
Cell lysates were prepared with cold RIPA buffer
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.15% SDS, 1 mM phenyl-
methylsulfonyl fluoride, phosphatase inhibitor, and
protease inhibitor cocktail). Proteins were resolved in
10% SDS-PAGE and transferred to polyvinylidene
difluoride membranes (Millipore). The membrane was
blocked and incubated with specific primary antibodies.
After incubating with secondary antibodies, the blots
were detected using ImmobilonTM Western Chemilu-
minescent HRP Substrate (EMD Millipore, MA).
Analysis of LPS-induced neuroinflammation after DMF
treatment
Adult Cx3cr1gfp/+ mice were randomly assigned to differ-
ent treatment groups and intraperitoneally (ip) injected
with 0.9% saline or LPS (1 mg/Kg). For the DMF-treated
group, mice were administered DMF (45 mg/Kg, ip) at
1 h before and 8 h after LPS injection [23, 24]. The ip
administration route was performed to achieve higher
bioavailability of DMF during shorter period of time
after dosing and to decrease the potential stress to the
sick LPS-treated mice. The brains were harvested 24 h
post-injection. For imaging analysis, the harvested brains
were fixed with 4% paraformaldehyde and cryoprotected
with 30% sucrose. Serial 15-μm frozen sections were cut
in a cryostat, mounted on superfrost plus slides, and
stored at − 20 °C until use. Brain slides were prepared
with ProLong Gold anti-fade mountant (Invitrogen). The
fluorescence microscope BX53 (Olympus, PA), Nuance
FX multispectral imaging system, and Nuance software
(PerkinElmer) were used for image acquisition and
analysis. For FACS analysis, brain mononuclear cells
were isolated as previously described [21, 25]. The iso-
lated cells were incubated with an antibody cocktail
containing anti-CD86, CD80, and CD40. After staining,
cells were subjected to FACS analysis. Mononuclear cell
populations, including MG and infiltrating immune
cells, were gated as GFP+ cells. For analysis of pro-
inflammatory cytokines, the harvested brains were
homogenized and subjected to RNA isolation. The ex-
pression levels of inflammatory mediators were mea-
sured using qPCR with interested TaqMan gene
expression probes.
Cell viability assay
Primary MG were treated with DMF (0, 10, and
100 μM) for 1 h followed by LPS (1 μg/ml) stimulation.
To produce LPS/DMF-free conditioned-medium (CM),
the culture medium was changed to neurobasal medium
(Life Technologies, CA) containing 2 mM L-glutamine
and 1 × N2 supplement (Life Technologies, CA) at 6 h
after LPS stimulation to wash out LPS and DMF. The
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microglial CM was collected 24 h after LPS. The micro-
glial CM was applied to differentiate HT22 hippocampal
neurons. Mouse HT22 hippocampal neurons were dif-
ferentiated as previously described before exposed to
microglial CM [21]. At 24 h after incubating with micro-
glial CM, the viability of neurons was examined using a
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay.
Mitochondrial membrane potential measurement
The mitochondrial membrane potential was detected
using fluorescent probe JC-1. Cells were incubated with
10 μg/ml of JC-1 dye for 10 min at 37 °C followed by
PBS wash. Healthy cells with polarized mitochondria
predominantly exhibited orange-red fluorescence due to
an aggregated form of JC-1 (Ex 535 nm, Em 590 nm).
When cells contained depolarized mitochondria, they
displayed green fluorescence reflected by a monomeric
form of JC-1 (Ex 485 nm, Em 530 nm). Six to eight fields
from each treatment group in an experiment were
acquired using inverted fluorescence microscope
DMI6000B with an attached digital camera (Leica Micro-
systems, IL).
Immunohistochemistry
The mouse brains were harvested and processed to pre-
pare brain sections as previously described [21, 25].
Brain sections were blocked and incubated with primary
antibodies, rabbit anti-Iba1 (1:2500, WAKO, VA), or
rabbit anti-GFAP (1:3000, Cell Signaling, Danvers, MA)
for 2 h at RT. After the secondary antibody incubation,
slides were developed with 3,3′-diaminobenzidine (DAB)
liquid substrate (DAKO, CA). Then, slides were counter-
stained with Mayer’s hematoxylin (Sigma-Aldrich) and
mounted with Permount (FisherSci). Two brain sections
from each mouse were stained and analyzed. Stained
slides were imaged (microscope: BX53, camera: DP72,
Olympus) and analyzed using CellSens software (Olym-
pus) by an experimenter blinded to experimental
conditions.
Novel object recognition test
The test was performed using a square arena (50 cm ×
50 cm × 34.5 cm). Adult C57BL/6J mice were randomly
assigned to different treatment groups. Mice were han-
dled for 3 days for habituation of handling. Mice were
then acclimated to the arena over 3 days, one 10-min
trial per day. Mice were subjected to a single-dose LPS
(1 mg/Kg, ip) injection. DMF (30 mg/Kg, ip) was admin-
istered every other day for 3 days as indicated. The
changes of body weight were measured daily to monitor
mice recovering from sickness following LPS injection.
Four days after LPS injection, mice were exposed to the
same arena containing two identical objects (henceforth
“familiar” object) for 10 min, as the acquisition session.
Twenty-four hours after the acquisition, the recognition
session was performed by replacing one of the familiar ob-
jects with a novel object. Any-maze software (Stoelting, IL)
was used to track and analyze the movements of the mice.
The behavioral experiments were performed by researchers
blinded to treatment groups. Results were expressed as per-
centage of time exploring each object.
Statistical analysis
Data are presented as mean ± SEM. For in vivo studies
with the groups containing ≥ 7 mice, a normal distribu-
tion of the data was confirmed by Shapiro-Wilk normal-
ity test. Comparisons between two groups were done
using the unpaired t test, whereas comparisons between
multiple groups were done by one-way ANOVA
followed by Bonferroni post hoc test using GraphPad
Prism software. Statistical significance was determined
with p values < 0.05.
Results
DMF suppresses inflammatory activation of MG
We first asked whether DMF is capable of modulating
phenotypes of MG in response to LPS stimulation. We
examined expressions of maturation markers, CD86,
CD80, and CD40, on MG cells stimulated with LPS in
the absence or presence of DMF. The LPS stimulation
induced microglial activation resulting in the increase of
these surface markers, whereas DMF treatment signifi-
cantly suppressed these markers in a dose-dependent
manner (Fig. 1a and Additional file 2: Figure S2A). In
addition, DMF was able to inhibit morphological
changes and Iba1 upregulation in MG stimulated with
LPS (Fig. 1b). The concentrations of DMF used in these
studies did not affect the cell viability of MG, suggesting
that the suppressive effect of DMF on MG is not medi-
ated through cytotoxicity (Additional file 1: Figure S1B).
DMF is shown as a strong inducer of Nrf2 in animal
models of MS [16, 17]. We also found that the expressions
of Nrf2 target genes were significantly upregulated in MG
treated with DMF (Fig. 1c). To investigate whether Nrf2
mediates actions of DMF in MG, we compared effects of
DMF on Nrf2+/+ and Nrf2−/− MG stimulated with LPS. In
Nrf2+/+ MG, LPS stimulation slightly increased the level
of Nrf2 protein, but not its downstream target, HO-1
(Fig. 1d). The DMF treatment significantly upregulated
the protein levels of Nrf2 and HO-1. In contrast, Nrf2−/−
MG did not exhibit induction of Nrf2 nor HO-1, after be-
ing treated with DMF, demonstrating the deficiency of
Nrf2. We next analyzed the effects of DMF on Nrf2−/−
MG stimulated with LPS. The DMF suppressed the induc-
tion of surface markers in Nrf2−/− MG after LPS stimula-
tion, similar to its action on Nrf2+/+ MG (Fig. 1e and
Additional file 2: Figure S2B). These results indicate that
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Fig. 1 (See legend on next page.)
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DMF might act on multiple pathways to modulate micro-
glial phenotype in response to LPS stimulation.
The release of pro-inflammatory cytokines indicates
activated MG moving towards an inflammatory pheno-
type. Further analyzing expressions of cytokines, we found
that DMF suppressed LPS-induced mRNA expressions of
TNF-α, IL-1β, iNOS, IL-23p19, and IL-12p40 in Nrf2+/+
MG (Fig. 1f). DMF was capable of suppressing the induc-
tion of inflammatory mediators in Nrf2−/− MG stimulated
with LPS. We noticed that the suppressive effect of DMF
on some of the inflammatory mediators in Nrf2−/− MG
was not as powerful as its suppressive action in Nrf2+/+
MG. Taken together, these results suggest that DMF sup-
presses inflammatory activation of reactive MG induced
by LPS potentially through both Nrf2-dependent and
Nrf2-independent mechanisms.
DMF inhibits LPS-induced NF-κB activation in MG
NF-κB regulates the transcription of a variety of pro-
inflammatory genes in different immune cells. To test
whether DMF acts on NF-κB signaling pathway to regu-
late microglial phenotypes, we examined the nuclear
translocation of NF-κB p65 induced by LPS in the absence
or presence of DMF. When stimulated with LPS, about
80% of MG cells exhibited nuclear p65 immunoreactivity
(Fig. 2a, b). DMF treatment significantly suppressed nu-
clear translocation of p65 in both Nrf2+/+ and Nrf2−/− MG
stimulated with LPS. Notably, Nrf2−/− MG exhibited a
higher level of p65 nuclear translocation at the resting
state and upon LPS stimulation, suggesting that Nrf2 defi-
ciency might promote inflammatory phenotypes of MG.
In addition, DMF abolished LPS-induced phosphorylation
of IKK-α/β in both Nrf2+/+ and Nrf2−/− MG (Fig. 2c).
Taken together, these results demonstrate the Nrf2-
independent mechanisms mediating actions of DMF to
suppress LPS-induced NF-κB activity in MG.
DMF reduces MG-mediated neurotoxicity
We next asked whether manipulating microglial pheno-
types and functions by DMF can foster neuroprotection.
We exposed differentiated HT22 hippocampal neurons to
CM derived from MG stimulated with LPS in the absence
or presence of DMF. After 24 h of exposure, there was a
substantial reduction in cell viability of neurons incubated
with CM generated from LPS-primed MG (Fig. 3a). The
induction of inflammatory phenotype in MG was exam-
ined after collecting CM, showing increased iNOS protein
in MG stimulated with LPS (Additional file 2: Figure
S2C). The DMF treatment was able to suppress the LPS-
induced iNOS in MG. When MG were stimulated with
LPS in the presence of DMF, they generated less toxic
CM, resulting in more survived neurons after incubation.
In consistent with neuronal cell viability, neurons exposed
to CM derived from LPS-primed MG showed increased
Caspase-3 activation, indicating increased neuronal cell
death induced by microglial CM (Fig. 3b, c). In contrast,
the CM generated from DMF-treated MG did not induce
significant Caspase-3 activation in neurons compared to
the vehicle-treated controls.
Mitochondrial dysfunction plays a critical role in the de-
generation and death of neurons [26]. We monitored
mitochondrial health status using molecular probe JC-1 to
distinguish energized (high membrane potential) and de-
energized mitochondria (membrane depolarization) in
neurons after short-term (6 h) exposure to microglial CM
(Fig. 3d). Incubating neurons with CM generated from
LPS-primed MG resulted in a shift of JC-1 fluorescence
emission from orange red (JC-1 aggregates) to green (JC-1
monomer). These data indicate that CM from LPS-
primed MG leads to disrupted membrane potential of
mitochondria in neurons. In contrast, the CM generated
from DMF-treated MG did not significantly cause mito-
chondrial abnormalities in neurons. Taken together, our
results demonstrate that DMF might protect neurons
from inflammatory insults by modulating toxic factors re-
leased from reactive MG associated with inflammation.
DMF suppresses LPS-induced acute neuroinflammation
To investigate whether DMF modulates microglial acti-
vation in vivo, we treated Cx3cr1gfp/+ mice with a single
(See figure on previous page.)
Fig. 1 DMF suppresses LPS-induced reactive MG. Primary MG were stimulated by LPS (100 ng/ml) in the absence or presence of DMF for various
time periods. a Microglial surface markers, CD86, CD80, and CD40, were examined at 18 h after stimulation using FACS analysis. Representative
flow plots from five independent experiments are shown. ISO, the isotype control antibody. MED, cell culture medium. b Morphological changes
of MG at 18 h after stimulation were examined using Iba1 immunostaining. Arrows indicate activated MG with increased expression of Iba1 and
enlarged cell bodies. Cell nuclei were stained blue with Hoechst 33342. Scale bar, 20 μm. c The expressions of DMF-induced Nrf2 target genes
were examined at 3 h after stimulation. The mRNA levels of hmox1, nqo1, gclc, and gclm were quantified using qPCR. Data presented are from 3
to 5 independent experiments. *p < 0.05, **p < 0.01, by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. d The Nrf2+/+ and
Nrf2−/− microglial cells were harvested for western blot analysis to examine Nrf2 and HO-1 proteins at 1.5 and 5 h after stimulation. Representative
results are shown from three independent experiments. e The CD86, CD80, and CD40 expressed on the surface of Nrf2−/− MG were examined at 18 h after
stimulation using FACS analysis. Representative flow plots from three independent experiments are shown. f Expressions of inflammatory mediators were
examined in Nrf2+/+ and Nrf2−/− MG at 3 h after stimulation. The mRNA levels of tnf, il1b, nos2, il23a, and il12b in treated MG were quantified using qPCR.
Data presented are from three independent experiments. *p< 0.05, **p< 0.01, ***p< 0.001, by one-way ANOVA with Bonferroni’s post hoc multiple
comparison test.
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dose of LPS injection (1 mg/Kg, ip) and examined the
brain 24 h post-injection. The LPS injection led to in-
creased GFP+ cells in the hippocampus of the brain,
indicating acute neuroinflammation in response to
LPS challenge (Fig. 4a). The administration of DMF
was able to reduce numbers and morphological
changes of GFP+ cells in the hippocampus. We further
isolated brain mononuclear cells and examined
maturation markers of GFP+ cells, which include activated
MG and potentially infiltrating peripheral immune
cells, such as monocytes/macrophages, following LPS
challenge. The LPS challenge significantly upregulated
CD80 expression on GFP+ cells, whereas DMF
treatment reduced CD80 upregulation induced by LPS
challenge (Fig. 4b, c). The expressions of CD86 and CD40
on the surface of GFP+ cells were not increased, while
examined at 24 h after LPS challenge (data not
shown). In addition, DMF treatment significantly sup-
pressed de novo cytokine production within the brain
following peripheral LPS challenge (Fig. 4d). Intriguingly,
the suppressive effect of DMF on brain-derived inflamma-
tory cytokine was blunted in LPS-challenged Nrf2−/− mice.
The suppression of IL-1β and TNFα mRNAs by DMF
treatment was partially retained in Nrf2−/− mice. However,
the suppression of Ccl2 mRNA by DMF treatment
was not observed in Nrf2−/− mice. These data indicate
that the Nrf2-dependent mechanism mediates the
actions of DMF to suppress acute neuroinflammation
induced by LPS. Taken together, these results suggest
that DMF treatment alleviates acute inflammatory
responses in the brain induced by peripheral LPS
challenge.
a
b
c
Fig. 2 DMF acts on Nrf2-independent mechanisms to suppress NF-κB activation induced by LPS. Primary Nrf2+/+ and Nrf2−/− MG were stimulated
with LPS (100 ng/ml) in the absence or presence of DMF (100 μM) for various time periods. a Nuclear translocation of NF-κB (p65) was examined
at 15 min after stimulation. Representative images of p65 immunostaining from three independent experiments are shown. Hoechst 33342-stained
cell nuclei are depicted in blue. MED, cell culture medium. VEH, vehicle control. Scale bar, 20 μm. b The percentage of p65-positive nuclei/total
cell nuclei in each treatment group was quantified. Data presented are from three independent experiments. ***p < 0.001, by one-way ANOVA
with Bonferroni’s post hoc multiple comparison test. c The western blot analysis of phospho-IKKα/β at 15 or 30 min after stimulation. Data presented
are representative blots from three independent experiments
Paraiso et al. Journal of Neuroinflammation  (2018) 15:100 Page 7 of 14
DMF alleviates cognitive deficits induced by systemic
immune challenge
We further investigated whether DMF treatment can al-
leviate the impairment of cognition driven by systemic
inflammation. We treated mice with a single dose of
LPS (1 mg/Kg, ip) and administered three doses of DMF
(30 mg/Kg, ip) as shown in Additional file 3: Figure S3A.
The changes of body weight were monitored daily to
ensure that mice recovered from transient sickness after
LPS injection (Additional file 3: Figure S3B). At 5 days
after LPS challenge, mice were subjected to the novel
object recognition task (Fig. 5a). The 24-h delayed
paradigm was used to access the long-term memory
function [27]. Mice that received saline injection showed
a clear preference for the novel object, but mice that re-
ceived LPS injection did not (Fig. 5b). The total explora-
tory or locomotor activity in mice was not affected at
the time when tasks were performed (Additional file 3:
Figure S3C). These results show that LPS-treated mice
were not able to distinguish between the novel and fa-
miliar objects, indicating an impairment in recognition
memory. In contrast, mice that received DMF treatment
following LPS challenge exhibited a preference towards
the novel object, suggesting that DMF treatment rescues
a
b
d
c
Fig. 3 DMF suppresses MG-mediated neurotoxicity. MG were stimulated with LPS (1 μg/ml) in the absence or presence of DMF. Microglial CM
was collected and applied to cultured hippocampal neurons. Neurons were exposed to microglial CM for 24 h. a The cell viability was assessed by
MTT assay. Data presented are from four independent experiments. *p < 0.05, **p < 0.01, by one-way ANOVA with Bonferroni’s post hoc multiple
comparison test. b The Caspase-3 activation was examined by immunostaining to detect cell death in neurons. Cell nuclei were stained blue with
Hoechst 33342. Representative images are from three independent experiments. MED, cell culture medium. VEH, vehicle control. Scale bar, 20 μm. c The
cleaved Caspas-3+ cells were quantified and compared with total cells (Hoechst-stained cells). Data presented are percentage of cleaved Caspas-3+ cells in
each treatment group. Results presented are from three independent experiments. *p< 0.05, **p< 0.01, ***p < 0.001, by one-way ANOVA with Bonferroni’s
post hoc multiple comparison test. d Representative images show a shift of JC-1 fluorescence from orange red (mitochondrial membrane polarized) to
green (mitochondrial membrane depolarized) in neurons incubated with CM from LPS-primed MG for 6 h. Neurons incubated with the CM generated
from DMF-treated MG (100 μM) show decreased JC-1 green fluorescence. MED, cell culture medium. VEH, vehicle control. Scale bar, 40 μm. Results are from
three independent experiments
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the long-term memory deficits caused by systemic im-
mune challenge.
Moreover, we examined Nrf2−/− mice that were sys-
temically challenged with LPS and subjected to novel
object recognition task. We observed exacerbation of
sickness with significant weight loss and increased mor-
tality rate (about 20–30%) following LPS challenge in
Nrf2−/− mice (Additional file 3: Figure S3D), suggesting
that Nrf2 plays an important role in alleviating systemic
inflammation. The Nrf2−/− mice exhibited the impair-
ment in recognition memory regardless of LPS challenge
(Fig. 5c and Additional file 3: Figure S3E). The adminis-
tration of DMF, although was not able to fully rescue the
memory deficits, tended to mitigate effects of LPS
challenge. These results suggest that Nrf2 dysfunction
might alter the cognitive function of the brain.
DMF suppresses chronic neuroinflammation associated
with systemic immune challenge
The systemic immune responses, although being re-
solved, still led to a long-lasting impact to the brain.
There was a slight increase of Iba1-expressing MG in
the hippocampus of LPS-treated mice, compared to
saline- or DMF-treated mice, even 2 weeks after LPS
injection (Fig. 6a, c). It is noteworthy that we observed
profound GFAP+ astrocytes in the hippocampus of
LPS-treated mice compared to saline-injected mice
(Fig. 6b, d). The GFAP+ astrocytes were significantly
a
b
d
c
Fig. 4 DMF reduces LPS-induced acute neuroinflammation. Cx3cr1gfp/+ mice were treated with a single-dose LPS injection (1 mg/Kg, ip). DMF
(45 mg/Kg) was administered through ip injection. At 24 h after LPS injection, the mouse brains were harvested and subjected to analyses. a Representative
images show GFP+ cells in the hippocampus of Cx3cr1gfp/+ mice that received saline, LPS + vehicle (VEH), or LPS + DMF treatment. N= 7 mice/group. Cell
nuclei were stained with DAPI (blue). Scale bar, 40 μm. b Mononuclear cells were isolated from the brain homogenates and subjected to FACS analysis.
The levels of CD80 marker on gated GFP+ cell populations were examined. Representative flow plots from three treatment groups, saline, LPS + VEH, LPS
+ DMF are shown. N= 7 mice/group. ISO, the isotype control antibody. c The proportion of CD80+ cells was determined. N= 7 mice/group. **p< 0.01,
***p< 0.001, by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. d Effects of DMF treatment on inflammatory mediators induced by
LPS injection in Nrf2+/+ (Cx3cr1gfp/+) or Nrf2−/− mice. The mRNA levels of pro-inflammatory cytokines or chemokine (tnf, il1b, or ccl2) in the brain were
measured using qPCR. N= 7 mice/group for Nrf2+/+ mice. N= 5–6 mice/group for Nrf2−/− mice. *p< 0.05, **p< 0.01, by one-way ANOVA with Bonferroni’s
post hoc multiple comparison test.
Paraiso et al. Journal of Neuroinflammation  (2018) 15:100 Page 9 of 14
reduced in the hippocampus of DMF-treated mice.
These results indicate that systemic immune challenge
triggers robust but sustained responses in astrocytes and
that DMF administration alleviates reactive astrocytes in
response to inflammation. A recent study shows that
TNFα, IL-1α, and C1q released from inflammatory MG
transform astrocytes towards neurotoxic A1 astrocytes
[28]. We analyzed whether DMF modulates expressions
of IL-1α and C1q in the brain following peripheral LPS
challenge. In addition to TNFα, DMF treatment signifi-
cantly reduced the expressions of IL-1α and C1q in the
brain induced by LPS injection (Fig. 6e). We further
tested whether DMF mitigates A1 phenotype in primary
astrocytes. In vitro, TNFα and IL-1α were able to induce
A1 astrocyte specific genes, including ggta1, h2-d1, and
serping1. The expression of these genes was suppressed
in DMF-treated astrocytes (Fig. 6f ). Taken altogether,
these results suggest that the protective effect of DMF
on rescuing neuronal dysfunction in LPS-challenged
mice might potentially be mediated through its
suppressive effect on the generation of neurotoxic A1
astrocytes.
Discussion
In the present study, we investigated the translational
potential of DMF for the treatment of cognitive impair-
ment associated with systemic inflammation. DMF ex-
erts distinct neuroprotective effects and clinical efficacy
for the treatment of relapsing-remitting MS [13, 14].
Here, we report a direct modulatory effect of DMF on
inflammatory MG induced by LPS. DMF effectively sup-
presses maturation markers, morphological changes, and
production of inflammatory mediators in cultured MG.
In line with our results, several studies also report that
DMF shows effective suppression on LPS-induced pro-
duction of inflammatory cytokines in human fetal and
adult MG cultures and in murine MG cultures [29, 30].
As a consequence of inflammatory activation, the toxic
factor released from reactive MG is able to induce
neurotoxicity [31]. We show that the CM from LPS-
primed MG induces Caspase-3 activation in neurons
after 24 h of exposure, while shorter time of exposure
(6 h) results in disrupted mitochondrial membrane
potential in neurons. DMF reduces inflammatory pheno-
type of MG and ameliorates MG-mediated neurotoxicity.
Similar to our results, DMF is reported to reduce neuronal
dysfunction through mitigating inflammatory activation of
MG induced by LPS [32]. MMF is shown to preserve
neuronal viability through modulating microglial pheno-
type stimulated with virus-infected monocytes [33].
In addition to in vitro studies, we identify that DMF
reduces acute neuroinflammation following peripheral
LPS challenge in mice. DMF administration reduces
morphological changes and maturation marker induc-
tion in brain-associated immune cells, including resident
and infiltrating immune cells, following LPS challenge.
Given that DMF is reported to suppress M1 polarization
of monocytes/macrophages in different disease models,
we speculate that the reduced neuroinflammation in
LPS/DMF-treated mice could be contributed by the
actions of DMF on peripheral immune cells [19, 34].
LPS is a strong activator of Toll-like receptor 4 signal-
ing, which induces inflammatory mediators robustly.
a
b
c
Fig. 5 DMF treatment alleviates cognitive deficits following systemic
immune challenge. a This figure illustrates the novel object recognition
task using a 24-h retention interval. b Adult C57BL/6 mice were
subjected to saline or LPS injection. DMF or vehicle (VEH) treatment
was administered every other day for 3 days following LPS injection. At
5 days after LPS injection, the mice were subjected to the novel object
recognition task. The time that mice spent with familiar or novel object
was measured. Percentage of exploration time on the object was
calculated. N = 10–16 mice/group. *p < 0.05, **p < 0.01, compared to
familiar object by unpaired Student’s t test. Data of saline, LPS + VEH,
and LPS + DMF treatment are from three independent experiments; data
of saline + DMF treatment are from two independent experiments.
c Adult Nrf2−/− mice were subjected to saline, LPS + VEH, or LPS + DMF
injection as described. At 5 days after LPS injection, the mice were
subjected to the novel object recognition task. The time that mice spent
with familiar or novel object was measured. Percentage of exploration
time on the object was calculated. N= 8–12 mice/group. There was no
statistical significance between the familial and the novel object when
data were analyzed by unpaired Student’s t test. Data presented are from
two independent experiments
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Excessive pro-inflammatory cytokines in the brain can
impair neuronal viability and lead to cognitive dysfunc-
tion [35–39]. DMF administration significantly sup-
presses the expression of pro-inflammatory cytokines in
the brain following peripheral LPS challenge, supporting
its potential to ameliorate cognitive dysfunction associ-
ated with systemic inflammation [40, 41]. Our results
provide promising evidence that DMF treatment rescues
deficits in long-term recognition memory affected by
systemic inflammation.
Several studies have reported that Nrf2-independent
mechanisms mediate the action of DMF [19, 32, 42, 43].
In this study, we also observe that Nrf2-independent ac-
tions of DMF modulate inflammatory MG and neuroin-
flammation in mice following LPS challenge. However,
we acknowledge that the suppressive effect of DMF on
LPS-induced neuroinflammation is blunted in Nrf2−/−
mice. Nrf2 is reported exhibiting immunomodulatory
and anti-inflammatory activities in T cells [44]. The
nuclear factor NF-κB is a key transcription factor regu-
lating immune responses. It is known that there is a
cross-talk between Nrf2 and NF-κB signaling pathways
[45]. Activation of Nrf2 attenuates NF-κB activity, which
is possibly mediated by HO-1-derived bilirubin in
a c
b
e f
d
Fig. 6 DMF alleviates reactive astrogliosis following systemic immune challenge. a Iba1+ MG and b GFAP+ astrocytes were examined by
immunohistochemistry at 2 weeks after a single-dose LPS injection. DMF was administered every other day for 3 days following LPS injection.
Representative images show the hippocampus of mice from three treatment groups, saline, LPS + VEH, LPS + DMF. N = 4–5 mice/group. High
magnification images of circled areas are shown at the lower panel. Quantification results of c Iba1+ MG and d GFAP+ astrocytes are shown. *p
< 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. Scale bar, 200 μm (low magnification)
or 20 μm (high magnification). e The mRNA levels of inflammatory molecules, il1a and c1qa, in the brain were quantified using qPCR. N = 7
mice/group. *p < 0.05, ***p < 0.001, by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. f Enriched astrocyte cultures were
stimulated with TNFα (30 ng/ml) and IL-1α (3 ng/ml) in the absence or presence of DMF. The expressions of A1 signature genes were measured at
24 h after stimulation. The mRNA levels of ggta1, h2-d1, and serping1 were quantified using qPCR. Data presented are from three independent
experiments. **p < 0.01, ***p < 0.001, by one-way ANOVA with Bonferroni’s post hoc multiple comparison test.
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endothelial cells [46]. Nrf2 knockdown is associated with
increased MafK activity, which positively promotes p65
acetylation and its subsequent transactivation activity in
hepatocytes [47]. Our findings provide the evidence of
cross-talk between Nrf2 and NF-κB signaling pathways
in MG. The deficiency of Nrf2 in MG results in a higher
level of p65 nuclear translocation at the resting state.
This result suggests potential role of Nrf2 in regulating
the intrinsic homeostasis of MG. Moreover, Nrf2−/− mice
show exaggerated sickness response to LPS challenge,
demonstrating the important role of Nrf2-mediated anti-
inflammatory responses.
When examining long-term effects of peripheral LPS
challenge to the brain, we observed profound reactive
astrocytes in the hippocampus of LPS-treated mice. It is
noteworthy that astrocytes are able to produce chemo-
kine Ccl2 in response to cytokine stimulation in animal
models. The astrocyte-derived chemokine Ccl2 is found
to recruit circulating Ccr2+ monocytes infiltrating into
the brain, which exacerbates the degeneration of
neurons [48, 49]. DMF administration significantly sup-
presses transcription of Ccl2 mRNA in the brain in-
duced by LPS challenge. Our results suggest potential
modulatory effects of DMF on astrocytes. In line with
our findings, DMF, but not MMF, is shown to reduce
the secretion of Ccl2 from cultured astrocytes stimulated
with pro-inflammatory cytokines [50]. Moreover, we ob-
served that DMF inhibits expressions of essential mole-
cules required for the generation of neurotoxic A1
astrocytes, including TNFα, IL-1α, and C1q, in the
mouse brain following LPS challenge. Our subsequent
examinations showed that the induction of A1 signature
genes is suppressed by DMF treatment in cultured
astrocytes, suggesting the action of DMF-regulating
astrocyte phenotypes. Genetic over-expression of Nrf2 in
astrocytes is reported to rescue neurodegeneration in the
amyotrophic lateral sclerosis (ALS) animal model [51]. It
would require further investigation to examine the potential
of DMF regulating phenotypic or functional polarization of
reactive astrocytes associated with neuroinflammation.
Systemic inflammation is reported to exacerbate pre-
existing conditions and accelerate cognitive decline in
several models of neurodegeneration including traumatic
brain injury and prion disease [52, 53]. We acknowledge
that the mice used in this study are young healthy
adults. Future studies to investigate effects of DMF on
systemic inflammation superimposed upon neurodegen-
erative conditions are warranted. Recent studies identify
that Nrf2 deficiency exacerbates cognitive deficits and
pathological features in mouse models of Alzheimer’s
disease [54–56]. Loss of Nrf2 in the mouse brain is
found to recapitulate the dysregulated pathways in
human aging and Alzheimer’s disease using the tran-
scriptomic analysis. In line with our findings of cognitive
impairment in Nrf2−/− mice, the long-term potentiation
is found decreased in the hippocampus of Nrf2−/− mice.
Although the dosing regimen we selected to treat LPS-
challenged Nrf2−/− mice is not able to fully rescue the
memory deficits, our results reveal a critical role of Nrf2
in the cognitive function and a potential of DMF as a
therapeutic strategy to fight Alzheimer’s disease.
Conclusions
The present study demonstrates that DMF attenuates
microglial responses towards the inflammatory phenotype
induced by LPS stimulation. The DMF treatment allevi-
ates the acute microglial activation, neuroinflammation,
long-term memory deficits, and responses of reactive as-
trocytes in mice following systemic immune challenge.
The DMF treatment has the translational potential to
protect neurons against toxic microenvironments in the
brain associated with systemic inflammation.
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